ArticlePloS one2015
Using Imiquimod-Induced Psoriasis-Like Skin as a Model to Measure the Skin Penetration of Anti-Psoriatic Drugs.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 78 citations in OpenAlex.
- Ethosomal Gel-Based Topical Delivery of Albendazole Hydrochloride for Psoriasis: In Vitro and In Vivo Evaluation.AAPS PharmSciTech · 2026Article
- Preparation of Tanshinone IIA and glycyrrhetinic acid emulsion and preliminary study on its anti-psoriasis efficacy.Drug delivery and translational research · 2026Article
- Question-Driven Selection of Psoriasis Animal Models: A Structured Narrative Review of 48 Model Records.Journal of inflammation research · 2026Review
- Induction of high numbers of TBMC immunology · 2025Article
- Assessment of antipsoriatic potential of novel pemetrexed disodium-loaded transdermal patches in an imiquimod-induced mouse model.Immunologic research · 2025Article
- Effects of topical isoxsuprine ointment on imiquimod-induced psoriasiform skin inflammation in mice.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Mitigative Effects of Topical Norfloxacin on an Imiquimod-Induced Murine Model of Psoriasis.ACS pharmacology & translational science · 2024Article
- Phenotypical and biochemical characterization of murine psoriasiform and fibrotic skin disease models in Stabilin-deficient mice.FEBS open bio · 2024Article
- Ameliorative effects of topical ramelteon on imiquimod-induced psoriasiform inflammation in mice.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Essential Oil ofClinical, cosmetic and investigational dermatology · 2024Article
- Fabrication and characterization of apremilast-loaded zinc oxide-mesoporous silica nanoparticles for psoriasis treatment.Therapeutic delivery · 2024Article
- Aggregation-Induced Emission-Active Photosensitizer-Mediated Photodynamic Therapy for Anti-Psoriasis.Research (Washington, D.C.) · 2024Article
- Topically applied pH-responsive nanogels for alkyl radical-based therapy against psoriasiform hyperplasia.Drug delivery · 2023Article
- Sericin-Based Poly(Vinyl) Alcohol Relieves Plaque and Epidermal Lesions in Psoriasis; a Chance for Dressing Development in a Specific Area.International journal of molecular sciences · 2022Article
- RETRACTED: Brevilin A Ameliorates Imiquimod-Induced Psoriasis-like Dermatitis and Reduces Th17 Differentiation in Psoriasis Patients.Journal of personalized medicine · 2022Article
- Spotlight on Calcipotriol/Betamethasone Fixed-Dose Combination in Topical Formulations: Is There Still Room for Innovation?Pharmaceutics · 2022Review
- The therapeutic effects ofJournal of traditional and complementary medicine · 2021Article
- Evaluating the effect of rice (Oryza sativa L.: SRNC05053-6-2) crude extract on psoriasis using in vitro and in vivo models.Scientific reports · 2020Article
- Shikonin inhibits CEBPD downregulation in IL‑17‑treated HaCaT cells and in an imiquimod‑induced psoriasis model.Molecular medicine reports · 2020Article
- Advanced Characterization of Imiquimod-Induced Psoriasis-Like Mouse Model.Pharmaceutics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePsoriasis is a chronic inflammatory skin disease and topical therapy remains a key role for treatment. The aim of this study is to evaluate the influence of psoriasis-like lesions on the cutaneous permeation of anti-psoriatic drugs.
methodsWe first set up imiquimod-induced dermatitis in mice that closely resembles human psoriasis lesions. The development of the lesions is based on the IL-23/IL17A axis for phenotypical and histological characteristics. Four drugs, 5-aminolevulinic acid (ALA), tacrolimus, calcipotriol, and retinoic acid, were used to evaluate percutaneous absorption.
resultsThe most hydrophilic molecule, ALA, revealed the greatest enhancement on skin absorption after imiquimod treatment. Imiquimod increased the skin deposition and flux of ALA by 5.6 to 14.4-fold, respectively, compared to normal skin. The follicular accumulation of ALA was also increased 3.8-fold. The extremely lipophilic drug retinoic acid showed a 1.7- and 3.8-fold increase in skin deposition and flux, respectively. Tacrolimus flux was enhanced from 2 to 21 μg/cm2/h by imiquimod intervention. However, imiquimod did not promote skin deposition of this macrolide. The lipophilicity, but not the molecular size, dominated drug permeation enhancement by psoriatic lesions. The in vivo percutaneous absorption of ALA and rhodamine B examined by confocal microscopy confirmed the deficient resistance of epidermal barrier for facilitating cutaneous delivery of drugs via psoriasis-like skin.
conclusionWe established the topical delivery profiles of anti-psoriatic drugs via imiquimod-treated psoriasis-like skin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.